Diabetes Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Diabetes Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Type 2 Diabetes
Metformin and TZDs improved fasting hepatic insulin sensitivity and glucose clearance
April 10th, 2006
Metformin and thiazolidinediones improved fasting hepatic insulin sensitivity and glucose clearance in type 2 diabetes. According to a review from Italy, "Insulin resistance, which manifests itself as endogenous glucose overproduction and reduced insulin-mediated glucose uptake, is a core defect in type 2 diabetes. Metformin and the peroxisome proliferator-activated receptor-gamma agonists, the thiazolidinediones (TZDs), both lower glucose, although their mechanism of action is still subject to debate. This review analyses the evidence relevant to these mechanisms in vivo." A. Natali and colleagues at the University of Pisa performed, "A systematic...
Source: Diabetes Week (2006-04-10)
|
